Ultra-sensitive diagnostics platform combining photodynamic therapy reagents with a digital readout

结合光动力治疗试剂与数字读数的超灵敏诊断平台

• 批准号: 104634
• 金额: $ 8.64万
• 依托单位: PSYROS DIAGNOSTICS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104634
• 关键词: Ultra; sensitive; diagnostics; platform; combining

"We now live in an age where personalised precision medicine is a reality for many patients, enabling better health outcomes. This personalisation requires access to appropriate diagnostic tools to select the right patients for the right treatment at the right time. Whilst a large number of disease markers are detectable using existing diagnostic tools for patient selection, there are still a significant number of disease areas which have eluded suitable testing in the clinical setting due to limited sensitivity of the tests. A few examples include circulating tumour markers, Cytokines, Alzheimer's disease markers, cardiac markers , infectious disease markers.Psyros are a newly formed spin-out from a Global Pharmaceutical company who had a large presence in precision medicine. The team have a very strong track record developing point of care _in-vitro_ diagnostics and recognise this unmet need of ultra-sensitive testing for precision medicine.In this project, we intend to prove the feasibility of a ground-breaking new concept for ultra-sensitive detection for use in diagnostics. When fully developed, this will open up opportunities for precision medicine for diseases where this is not currently possible, thereby improving the outcomes for patients and ultimately improving the quality of their lives."

“我们现在生活在一个时代，个性化的精准医疗对许多患者来说是一个现实，能够实现更好的健康结果。这种个性化需要获得适当的诊断工具，以便在正确的时间选择正确的患者进行正确的治疗。虽然使用现有的用于患者选择的诊断工具可以检测到大量的疾病标志物，但是由于测试的灵敏度有限，仍然存在大量的疾病区域在临床环境中无法进行合适的测试。Psyros是一家全球制药公司新成立的分支机构，该公司在精准医学领域拥有大量业务。我们的团队在体外诊断领域有着非常出色的记录，并认识到精密医疗对超灵敏检测的需求尚未得到满足。在这个项目中，我们打算证明一个突破性的新概念的可行性，即超灵敏检测用于诊断。一旦得到充分发展，这将为目前无法实现的疾病提供精准医疗的机会，从而改善患者的预后，并最终提高他们的生活质量。"